Diametric Capital, LP Bio Atla, Inc. Transaction History

Diametric Capital, LP

$173 Million
Q3 2024

A detailed history of Diametric Capital, LP transactions in Bio Atla, Inc. stock. As of the latest transaction made, Diametric Capital, LP holds 83,505 shares of BCAB stock, worth $44,257. This represents 0.08% of its overall portfolio holdings.

Number of Shares

83,505

Holding current value

$44,257

% of portfolio

0.08%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Nov 13, 2024	BUY	$1.17 - $2.05 $97,700 - $171,185	83,505 New	83,505 $146,000
Q1 2023 May 11, 2023	BUY	$2.3 - $8.25 $37,485 - $134,458	16,298 New	16,298 $43,000

Others Institutions Holding BCAB

# of Institutions

Shares Held

17.5M

Call Options Held

500

Put Options Held

33.5K

Israel Englander Millennium Management LLC | New York, Ny

2.66M
Shares

$1.41 Million
0.0% of portfolio
Soleus Capital Management, L.P. Greenwich, CT

2.52M
Shares

$1.33 Million
0.38% of portfolio
Vanguard Group Inc Valley Forge, PA

1.89M
Shares

$999,183
0.0% of portfolio
Morgan Stanley New York, NY

1.86M
Shares

$984,833
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

874K
Shares

$463,260
0.13% of portfolio

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $19.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Diametric Capital, LP with notifications on news.

Account